Siolta Therapeutics develops therapies through understanding of human microbial ecology. The company combines clinical data, bioinformatics, and microbial science to develop combinations of bacteria that target disease-specific mechanisms of action.

Siolta Therapeutics

Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutics to improve outcomes in conditions with unmet medical needs. Our offices and laboratory are located in San Carlos, CA.  

National Institute of Allergy and Infectious Diseases

Seventure Partners

Global Brain Corporation

Khosla Ventures

SymBiosis LLC

Marc Benioff

Thanks @Ilana Golant @foodallergyfund – I’m excited to join an amazing group of folks elevating the conversation on food allergies! The Annual Food Allergy Fund Summit, held in New York City on May 23rd, will highlight the latest advancements and cutting-edge developments in food allergy research and innovation. 

Check out the agenda and support the cause here: https://lnkd.in/gs2tzeKu

Looking forward to supporting industry-academia cross-pollination at the Joint Berkeley Initiative for Microbiome Science (JBIMS) next week on May 9th from 2:00 PM to 6:00 PM at the Bakar BioEngenuity Hub at UC Berkeley.

This event aims to strengthen ties between leading microbiome researchers from academia and dynamic industry players. RSVP here: https://lnkd.in/gXH85Uxe 

Thanks to Eoin Brodie, Britt Koskella, and Matt Traxler for keeping us all connected!

Thanks to all of you supporting our vision of a better world where our healthcare, including drug development, is focused on solutions that alleviate disease from the start!

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

https://lnkd.in/gzStYAHg

Metric
Company Name	Siolta Therapeutics
Symbol
MSH ID	COM:SIOLTATHERAPEUTICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	16
Website	sioltatherapeutics.com
LinkedIn	siolta-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SIOLTATHERAPEUTICS

Siolta Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue